<DOC>
	<DOCNO>NCT00816972</DOCNO>
	<brief_summary>This 1-week study desloratadine ( DL ) plus oxybutynin ( OXY ) two dose level treatment post-nasal drip participant seasonal allergic rhinitis . Participants receive either desloratadine twice day , oxybutynin twice day , desloratadine plus lower-dose oxybutynin twice day , desloratadine plus higher-dose oxybutynin twice day , placebo 7 day .</brief_summary>
	<brief_title>Desloratadine With Oxybutynin Treatment Seasonal Allergic Rhinitis Post-Nasal Drip ( Study P04258 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Subjects must : &gt; =18 year age , free clinically significant disease would interfere study , seasonal allergic rhinitis ( SAR ) , document diagnosis SAR &gt; =2 year , positive skinprick test , sufficiently symptomatic Screening visit , 3 calendar day immediately prior baseline visit , plus AM baseline visit , seven twicedaily runin diary PRIOR total nasal symptom score must total &gt; =42 , Total NonNasal Symptoms score must total &gt; =28 , total Post Nasal Drip score must total &gt; =14 , general good health . Subjects : certain medical condition medical history , allergy component study medication , nasal structure abnormality , dependency nasal , oral , ocular decongestant , nasal topical antihistamine , nasal steroid , use investigational drug use past 30 day , receive immunotherapy ( desensitization ) pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>